The candidate vaccine from Sanofi-GSK has successfully passed the phase two trial, announced this Monday morning on Europe 1 Olivier Bogillot, president of Sanofi France.

Phase three trials will begin in late May-early June, and at the same time, production.

For Europe, the doses will be manufactured in France in particular.

The production of the French vaccine from Sanofi-GSK is due to start in late May-early June, at the same time as the phase three trials.

For vaccines intended for Europe, Sanofi will produce at its European sites, and in particular in France, where the group has no less than 18 production plants.

The adjuvant essential for the manufacture of the vaccine will, for example, be produced in Vitry-sur-Seine, in Val-de-Marne.

>> LIVE

 -

Coronavirus: follow the evolution of the situation Monday, May 17

Objective: vaccinate from November

The group's production plants will also be mobilized around the world.

American bottles will, for example, be produced directly in the United States.

The goal is to produce several million doses by the end of the year.

>> Find Europe midi in replay and podcast here

Sanofi hopes that vaccination with its own vaccine can begin as early as November.

At the same time, the group will continue to produce bottles from competitors, such as that of Pfizer in Germany.